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EDITORIALS 
Selective Newodegeneration 
in Huntington's Disease 
In this issue of the Annals of Nearologli, hchfield and 
colleagues [ l )  publish the latest in a series of reports 
describing the preferential loss of a specific population 
of striatal neurons in Huntington's disease (HD). 
While careful neuropathological analyses have demon- 
strated neuron loss in many brain regions, the striatum 
is disproportionately affected in HD and work from 
several groups has now resulted in a fairly detailed un- 
derstanding of the pattern of striatal neurodegenera- 
tion in HD. This achievement was made possible by 
the recognition and description of diverse subpopula- 
tions of striatal neurons. 
Striatal neuron subpopulations are divided into two 
broad categories: interneurons whose axonal arboriza- 
tions stay within the striatum, and projection neurons 
with axons terminating in the pallidum or substantia 
nigra. Striatal projection neurons comprise the vast ma- 
jority of striatal neurons, perhaps 90%) in all, while 
there are several different subpopulations of striatal 
interneurons, each comprising a small fraction of stria- 
tal neurons. Three subpopulations of striatal interneu- 
rons are particularly well characterized: one subpopula- 
tion expressing somatostatin (SS), neuropeptide Y 
(NPY), and nitric oxide synthase (NOS); a second sub- 
population expressing acetylcholine; and a third y- 
aminobutyric acid (GABA)ergic subpopulation ex- 
pressing the calcium-binding protein parvalbumin. 
Studies of striatal interneurons provided the first evi- 
dence that not all striatal neurons are equally affected 
in HD. In 1985, work by two groups 12, 31 demon- 
strated that striatal SS/NPY/NOS neurons are at least 
relatively spared in HD. It was subsequently appreci- 
ated that while markers of striatal cholinergic function 
decline in HD, there is preservation of striatal cholin- 
ergic perikarya, indicating functional impairment but 
not degeneration of striatal cholinergic interneurons 
14). Harrington and Kowall {5] suggested that striatal 
GABAIparvalbumin-containing interneurons are pre- 
served early in the course of HD but degenerate with 
progression of HD. 
Striatal projection neurons are subdivided into sub- 
populations on the basis of their target regions and 
which neuropeptides they contain. Striatal projection 
neurons terminate in either the external segment of 
the globus pallidus (GPe), the internal segment of the 
globus pallidus (GPi), the substantia nigra pars reticu- 
lata (SNr), or the substantia nigra pars compacta (SNc) 
with few collaterals to other target regions. All striatal 
projection neurons are GABAergic but striato-GPe 
neurons express enkephalins while striato-GPi, striato- 
SNr, and striato-SNc neurons express tachykinins such 
as substance P. Initial findings by Reiner and cowork- 
ers [GI, now confirmed by &chfield and colleagues 
{l)  and other groups, indicated that striato-GPe and 
striato-SNr neurons degenerate preferentially early in 
the course of HD, with striato-GPi neurons relatively 
spared early in the course of HD. Remarkably, loss of 
striato-GPe neurons has been observed in presymp- 
tomatic HD 17). The early and relatively selective loss 
of striato-GPe and striato-SNr neurons is a plausible 
explanation for the chorea and oculomotor abnormali- 
ties that are prominent clinical features of early HD. 
Hedreen and Folstein {8) suggested recently that stri- 
ato-SNc neurons are affected even earlier in the course 
of HD than are striato-GPe neurons. While awaiting 
confirmation, this observation would complete an in- 
ferred model of disease progression in which striatal 
projection neurons degenerate in a specific temporal 
sequence: striato-SNc followed by striato-GPe and stri- 
ato-SNr, then followed by striato-GPi. Striatal GABA/ 
parvalbumin interneurons also degenerate with relative 
sparing, through functional impairment, of striatal cho- 
linergic interneurons and preservation of striatal SS/ 
NPY/NOS interneurons. Striatal afferent terminals, 
such as those of the nigrostriatal projection, appear to 
be relatively spared in HD.  
Knowledge of affected and spared striatal neuron 
subpopulations proved invaluable in assessing putative 
models of HD. The reproduction of many features 
of HD striatal pathology by intrastriatal injections of 
N-methybaspartate (NMDA) receptor agonists is 
strong evidence for an NMDA receptor/excitotoxic 
mechanism of neuronal degeneration in HD. The 
NMDA hypothesis is a rational basis for clinical experi- 
ments and is the point of departure for a large clinical 
trial being prepared by the Huntington's Study Group. 
The differences between brain regions and between 
striatal neuron subpopulations in their susceptibility to 
the pathogenetic process caused by abnormal HD al- 
leles is in marked contrast to the wide expression of 
the HD gene product "91. Both in situ hybridization 
studies of messenger RNA expression and immunohis- 
tochemical studies of the protein, huntingtin, encoded 
by the HD gene have shown uniform expression of this 
gene in all neurons examined and in several peripheral 
tissues. The abnormal gene product, characterized by 
expanded polyglutamine repeats near the amino termi- 
nus, is also expressed. The unique pattern of pathology 
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found in HD cannot be accounted for by the pattern 
of expression of huntingtin, and additional factors spe- 
cific to the affected neurons must account for the dif- 
ferential degeneration or survival of striatal and other 
neuron subpopulations. Intensive investigation of hun- 
tingtin is now under way and it is hoped that further 
characterization of this protein will lead to clues regard- 
ing the mechanism(s) of neurodegeneration. Some evi- 
dence, however, suggests that the abnormal gene prod- 
uct acts by a so-called gain of function effect in which 
the abnormal allele has gained a new and pathological 
effect, possibly unrelated to the function of the normal 
protein [9]. If so, discovery of the normal function of 
huntingtin may not cast light on the mechanism(s) of 
neuronal death. In any case, huntingtin has little ho- 
mology to known proteins and characterization of hun- 
tingtin function(s) may be an arduous process. 
Further investigation of the biology of striatal neu- 
rons should be pursued as a parallel approach to uncov- 
ering clues regarding neurodegeneration in HD. The 
clear differences in susceptibility among striatal neuron 
subpopulations suggest that broad-based investigation 
of the properties of striatal neuron subpopulations 
might reveal crucial differences between affected and 
spared striatal neuron subpopulations. To develop sci- 
entific strategies for arresting progression of HD, we 
need to understand the interplay between the abnor- 
mal gene product and the specific factors governing 
neuronal susceptibility. We may ultimately achieve a 
comprehensive understanding of neuronal degenera- 
tion in HD that will assist in understanding the mecha- 
nisms of neurodegeneration in other disorders. 
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